B
Bull
Bull · 25%COYA
$1.48
Szenariopreis
$4.590
-0.255 (-5.56%)Zum Schluss
Loading chart…
- High
- 4.820
- Open
- 4.820
- VWAP
- 4.65
- Vol
- 153.11K
- Mkt Cap
- 92.70M
- Low
- 4.550
- Amount
- 712.46K
- EV/EBITDA, TTM
- 312.60
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.
AI analysis of Coya Therapeutics Inc (COYA)
buyCoya Therapeutics Inc is a good buy right now, as it has a current price of $4.59, significantly below the analyst price target of $12, indicating a potential upside of 161%. Additionally, the company reported a revenue growth of 123.9% year-over-year, which shows strong product demand despite ongoing losses.
Bewertungskennzahlen
The current forward P/E ratio for Coya Therapeutics Inc (COYA) is 0.00, compared to its 5-year average forward P/E of -7.06.
Alphio AI Price Scenarios for COYA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding COYA
Event-Zeitleiste
News
6.006-05CNBCLatest Ratings and Outlook from Wall Street
9.505-12seekingalphaCoya Therapeutics Reports Q1 Financial Results with Increased Losses
9.505-12NewsfilterCoya Therapeutics Reports Q1 2026 Financial Results and Corporate Update
- 9.005-12Newsfilter
Coya Receives FDA Fast Track Designation for COYA 302
- 9.003-18Newsfilter
Coya Publishes Study Results on Frontotemporal Dementia
COYA FAQ — answered by Alphio AI
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Coya Therapeutics Inc is a good buy right now, as it has a current price of $4.59, significantly below the analyst price target of $12, indicating a potential upside of 161%. Additionally, the company reported a revenue growth of 123.9% year-over-year, which shows strong product demand despite ongoing losses.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.